Anti-CLDN18.2 ADC Receives FDA Fast Track Designation in Advanced PDAC
The FDA has granted fast track designation to the investigational TOPO1i anti-Claudin 18.2 (CLDN18.2) antibody drug conjugate (ADC) IBI343 as a treatment for patients with advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC), …